Dr. Zoubeidi led an international team that has published their discovery providing mechanistic insights into prostate cancer resistant to powerful hormone therapy, and proposes a potential treatment regime for reversing currently treatment-resistant phenotypes. This work was published online on September 6, 2021 in the high-impact journal Nature Cell Biology , along with a News and Views article focusing on this publication.
The team investigated a phenomenon in prostate cancer in which tumours can escape epithelial lineage confinement and transition to a high-plasticity state as an adaptive response to potent androgen receptor (AR) antagonism. Their study demonstrates that targeting both AR and EZH2 in patients with AR-positive, neuroendocrine-like tumours has the potential to reprogram aggressive tumours to a targetable state. This work highlights the clinical potential of reversing resistant phenotype.
This research was supported by funding from the Terry Fox Research Institute New Frontiers Program Project Grant (to A.Z.), the Prostate Cancer Foundation (to A.Z. and H.B.), and the Canadian Institutes of Health Research (399802 to A.D.)
Davies A, Nouruzi S, Ganguli D, Namekawa T, Thaper D, Linder S, Karaoğlanoğlu F, Omur ME, Kim S, Kobelev M, Kumar S, Sivak O, Bostock C, Bishop J, Hoogstraat M, Talal A, Stelloo S, van der Poel H, Bergman AM, Ahmed M, Fazli L, Huang H, Tilley W, Goodrich D, Feng FY, Gleave M, He HH, Hach F, Zwart W, Beltran H, Selth L, Zoubeidi A. An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Nat Cell Biol. 2021 Sep 6. doi: 10.1038/s41556-021-00743-5. Epub ahead of print. PMID: 34489572
News and Views: Xin L. EZH2 accompanies prostate cancer progression. Nat Cell Biol. 2021 Sep 6. doi: 10.1038/s41556-021-00744-4. Epub ahead of print. PMID: 34489575